These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26250462)

  • 21. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
    Mohammadi F; Shafiei M; Assad D; Rostami G; Hamid M; Foroughmand AM
    Iran Biomed J; 2021 Jan; 25(1):54-61. PubMed ID: 33129240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
    Kassogue Y; Quachouh M; Dehbi H; Quessar A; Benchekroun S; Nadifi S
    Med Oncol; 2014 Jan; 31(1):782. PubMed ID: 24293093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.
    Annuar AA; Ankathil R; Mohd Yunus N; Husin A; Ab Rajab NS; Abdul Aziz AA; Ibrahim MI; Sulong S
    Asian Pac J Cancer Prev; 2021 Feb; 22(2):565-571. PubMed ID: 33639675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients.
    Rinaldi I; Nova R; Widyastuti R; Priambodo R; Instiaty I; Louisa M
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3331-3334. PubMed ID: 31759356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C1236T polymorphism in MDR1 gene correlates with therapeutic response to imatinib mesylate in Indian patients with chronic myeloid leukaemia.
    Chhikara S; Sazawal S; Mishra P; Chaubey R; Mahapatra M; Saxena R
    Natl Med J India; 2015; 28(6):272-5. PubMed ID: 27294449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
    de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM
    Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
    Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
    Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
    Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
    Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of ABCB1 Gene (C3435T/A2677G) Polymorphic Sequence Variations on the Outcome of Patients with Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Kashmiri Population: A Case-Control Study.
    Baba SM; Pandith AA; Shah ZA; Geelani SA; Mir MM; Bhat JR; Bhat GM
    Indian J Hematol Blood Transfus; 2021 Jan; 37(1):21-29. PubMed ID: 33707832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
    Vivona D; Bueno CT; Lima LT; Hirata RD; Hirata MH; Luchessi AD; Zanichelli MA; Chiattone CS; Guerra-Shinohara EM
    Blood Cells Mol Dis; 2012 Feb; 48(2):132-6. PubMed ID: 22134106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.
    Zheng Q; Wu H; Yu Q; Kim DH; Lipton JH; Angelini S; Soverini S; Vivona D; Takahashi N; Cao J
    Pharmacogenomics J; 2015 Apr; 15(2):127-34. PubMed ID: 25245580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of DNA repair gene XPC Ala499Val (rs2228000 C>T) and Lys939Gln (rs2228001 A>C) polymorphisms with the risk of chronic myeloid leukemia: A case-control study in a South Indian population.
    Lakkireddy S; Aula S; Kapley A; Gundeti S; Kutala VK; Jamil K
    J Gene Med; 2021 Jul; 23(7):e3339. PubMed ID: 33829606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.
    da Cunha Vasconcelos F; Mauricio Scheiner MA; Moellman-Coelho A; Mencalha AL; Renault IZ; Rumjanek VM; Maia RC
    Leuk Res; 2016 Dec; 51():3-10. PubMed ID: 27770655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Vascular Endothelial Growth Factor A (VEGFA) and its Receptor (VEGFR2) Gene Polymorphisms with Risk of Chronic Myeloid Leukemia and Influence on Clinical Outcome.
    Lakkireddy S; Aula S; Kapley A; Swamy AV; Digumarti RR; Kutala VK; Jamil K
    Mol Diagn Ther; 2016 Feb; 20(1):33-44. PubMed ID: 26476544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.
    Annamaneni S; Gorre M; Kagita S; Addepalli K; Digumarti RR; Satti V; Battini MR
    Hematology; 2013 May; 18(3):163-8. PubMed ID: 23320983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
    Galeotti L; Ceccherini F; Domingo D; Laurino M; Polillo M; Di Paolo A; Baratè C; Fava C; D'Avolio A; Cervetti G; Guerrini F; Fontanelli G; Ciabatti E; Grassi S; Arrigoni E; Danesi R; Petrini M; Cornolti F; Saglio G; Galimberti S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):767-773. PubMed ID: 28289867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.